Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Teva Pharmaceuticals USA

Teva Pharmaceuticals USA Recalls

All product recalls associated with Teva Pharmaceuticals USA.

Get alerts for this brand

Recall Summary

Total Recalls

265

Past Year

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 141–160 of 265 recalls

Metformin Tablets (Teva) – Delivery System Defect (2018)

Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Class IIModerate

FDAAug 6, 2018Nationwide• Teva Pharmaceuticals USA

Pioglitazone Metformin Tablets (Teva) – Defective Delivery System (2018)

Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Class IIModerate

FDAAug 6, 2018Nationwide• Teva Pharmaceuticals USA

Metformin Tablets (Teva) – Defective Delivery System (2018)

Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

1...6 789 10...14

Page 8 of 14Next

Class IIModerate

FDAAug 6, 2018Nationwide• Teva Pharmaceuticals USA

Paliperidone Tablets (Teva) – Delivery System Defect (2018)

Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Class IIModerate

FDAAug 6, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Omega-3-Acid Ethyl Esters Capsules (Teva) – Unapproved API (2018)

API material used in the manufacturing of the product did not receive regulatory approval prior to release.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Fluocinolone Acetonide Solution (Teva) – Impurity Issues (2018)

Failed Impurities and Degradation Specifications and Subpotent Drug: out-of-specification (OOS) test results for below assay and above specification for degradants.

Class IIModerate

FDAJul 5, 2018Nationwide• Teva Pharmaceuticals USA

Lidocaine Patch 5% (Teva) – Stability Failure (2018)

Failed Stability Specifications

Class IIILow

FDAApr 30, 2018Nationwide• Teva Pharmaceuticals USA

Estradiol Vaginal Inserts (Teva) – Dispensing Difficulty (2018)

Defective Container: This recall is being initiated due to product complaints regarding difficulty in dispensing the tablet from the applicator.

Class IIModerate

FDAMar 19, 2018Nationwide• Teva Pharmaceuticals USA

Fluoxetine Tablets (Teva) – Impurity Concern (2018)

Failed impurities/ degradation specifications: Teva Pharmaceuticals USA, Inc. is voluntarily recalling all lots within expiry due to out of specification (OOS) test result for the lactoside impurity obtained during routine stability testing activities.

Class IIILow

FDAFeb 5, 2018Nationwide• Teva Pharmaceuticals USA

Fentanyl 25mcg Patch (Teva) – Degradation Risk (2018)

Failed Impurities/Degradation Specifications: Fentanyl-n-Oxide (FNO) degradant exceeding the specification limits

Class IIILow

FDAJan 29, 2018Nationwide• Teva Pharmaceuticals USA

Fentanyl 100mcg Patch (Teva) – Degradation Risk (2018)

Failed Impurities/Degradation Specifications: Fentanyl-n-Oxide (FNO) degradant exceeding the specification limits

Class IIILow

FDAJan 29, 2018Nationwide• Teva Pharmaceuticals USA